Biosimilar Insulin Market Report

Global Biosimilar Insulin Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Mar 10, 2022
  • PAGES：225
  • REPORT CODE：GMM818500
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Biosimilar Insulin market report explains the definition, types, applications, major countries, and major players of the Biosimilar Insulin market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Geropharm

    • Julphar Gulf Pharmaceutical Industries

    • Paras Biopharmaceuticals

    • Biogenomics

    • Teva Pharmaceuticals

    • Wockhardt

    • Samsung Bioepis

    • Gan&Lee Pharmaceuticals

    • Pfizer

    • Sedico

    • Eli Lilly

    By Type:

    • Rapid Acting Insulins

    • Short Acting Insulins

    • Intermediate Insulins

    • Long Lasting Insulins

    By End-User:

    • Hospital

    • Clinic

    • Medical Center

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Biosimilar Insulin Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Biosimilar Insulin Outlook to 2028- Original Forecasts

    • 2.2 Biosimilar Insulin Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Biosimilar Insulin Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Biosimilar Insulin Market- Recent Developments

    • 6.1 Biosimilar Insulin Market News and Developments

    • 6.2 Biosimilar Insulin Market Deals Landscape

    7 Biosimilar Insulin Raw Materials and Cost Structure Analysis

    • 7.1 Biosimilar Insulin Key Raw Materials

    • 7.2 Biosimilar Insulin Price Trend of Key Raw Materials

    • 7.3 Biosimilar Insulin Key Suppliers of Raw Materials

    • 7.4 Biosimilar Insulin Market Concentration Rate of Raw Materials

    • 7.5 Biosimilar Insulin Cost Structure Analysis

      • 7.5.1 Biosimilar Insulin Raw Materials Analysis

      • 7.5.2 Biosimilar Insulin Labor Cost Analysis

      • 7.5.3 Biosimilar Insulin Manufacturing Expenses Analysis

    8 Global Biosimilar Insulin Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Biosimilar Insulin Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Biosimilar Insulin Export by Region (Top 10 Countries) (2017-2028)

    9 Global Biosimilar Insulin Market Outlook by Types and Applications to 2022

    • 9.1 Global Biosimilar Insulin Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Rapid Acting Insulins Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Short Acting Insulins Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Intermediate Insulins Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Long Lasting Insulins Consumption and Growth Rate (2017-2022)

    • 9.2 Global Biosimilar Insulin Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinic Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Medical Center Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Biosimilar Insulin Market Analysis and Outlook till 2022

    • 10.1 Global Biosimilar Insulin Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Biosimilar Insulin Consumption (2017-2022)

      • 10.2.2 Canada Biosimilar Insulin Consumption (2017-2022)

      • 10.2.3 Mexico Biosimilar Insulin Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Biosimilar Insulin Consumption (2017-2022)

      • 10.3.2 UK Biosimilar Insulin Consumption (2017-2022)

      • 10.3.3 Spain Biosimilar Insulin Consumption (2017-2022)

      • 10.3.4 Belgium Biosimilar Insulin Consumption (2017-2022)

      • 10.3.5 France Biosimilar Insulin Consumption (2017-2022)

      • 10.3.6 Italy Biosimilar Insulin Consumption (2017-2022)

      • 10.3.7 Denmark Biosimilar Insulin Consumption (2017-2022)

      • 10.3.8 Finland Biosimilar Insulin Consumption (2017-2022)

      • 10.3.9 Norway Biosimilar Insulin Consumption (2017-2022)

      • 10.3.10 Sweden Biosimilar Insulin Consumption (2017-2022)

      • 10.3.11 Poland Biosimilar Insulin Consumption (2017-2022)

      • 10.3.12 Russia Biosimilar Insulin Consumption (2017-2022)

      • 10.3.13 Turkey Biosimilar Insulin Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Biosimilar Insulin Consumption (2017-2022)

      • 10.4.2 Japan Biosimilar Insulin Consumption (2017-2022)

      • 10.4.3 India Biosimilar Insulin Consumption (2017-2022)

      • 10.4.4 South Korea Biosimilar Insulin Consumption (2017-2022)

      • 10.4.5 Pakistan Biosimilar Insulin Consumption (2017-2022)

      • 10.4.6 Bangladesh Biosimilar Insulin Consumption (2017-2022)

      • 10.4.7 Indonesia Biosimilar Insulin Consumption (2017-2022)

      • 10.4.8 Thailand Biosimilar Insulin Consumption (2017-2022)

      • 10.4.9 Singapore Biosimilar Insulin Consumption (2017-2022)

      • 10.4.10 Malaysia Biosimilar Insulin Consumption (2017-2022)

      • 10.4.11 Philippines Biosimilar Insulin Consumption (2017-2022)

      • 10.4.12 Vietnam Biosimilar Insulin Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Biosimilar Insulin Consumption (2017-2022)

      • 10.5.2 Colombia Biosimilar Insulin Consumption (2017-2022)

      • 10.5.3 Chile Biosimilar Insulin Consumption (2017-2022)

      • 10.5.4 Argentina Biosimilar Insulin Consumption (2017-2022)

      • 10.5.5 Venezuela Biosimilar Insulin Consumption (2017-2022)

      • 10.5.6 Peru Biosimilar Insulin Consumption (2017-2022)

      • 10.5.7 Puerto Rico Biosimilar Insulin Consumption (2017-2022)

      • 10.5.8 Ecuador Biosimilar Insulin Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Biosimilar Insulin Consumption (2017-2022)

      • 10.6.2 Kuwait Biosimilar Insulin Consumption (2017-2022)

      • 10.6.3 Oman Biosimilar Insulin Consumption (2017-2022)

      • 10.6.4 Qatar Biosimilar Insulin Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Biosimilar Insulin Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Biosimilar Insulin Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Biosimilar Insulin Consumption (2017-2022)

      • 10.7.2 South Africa Biosimilar Insulin Consumption (2017-2022)

      • 10.7.3 Egypt Biosimilar Insulin Consumption (2017-2022)

      • 10.7.4 Algeria Biosimilar Insulin Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Biosimilar Insulin Consumption (2017-2022)

      • 10.8.2 New Zealand Biosimilar Insulin Consumption (2017-2022)

    11 Global Biosimilar Insulin Competitive Analysis

    • 11.1 Geropharm

      • 11.1.1 Geropharm Company Details

      • 11.1.2 Geropharm Biosimilar Insulin Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Geropharm Biosimilar Insulin Main Business and Markets Served

      • 11.1.4 Geropharm Biosimilar Insulin Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Julphar Gulf Pharmaceutical Industries

      • 11.2.1 Julphar Gulf Pharmaceutical Industries Company Details

      • 11.2.2 Julphar Gulf Pharmaceutical Industries Biosimilar Insulin Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Julphar Gulf Pharmaceutical Industries Biosimilar Insulin Main Business and Markets Served

      • 11.2.4 Julphar Gulf Pharmaceutical Industries Biosimilar Insulin Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Paras Biopharmaceuticals

      • 11.3.1 Paras Biopharmaceuticals Company Details

      • 11.3.2 Paras Biopharmaceuticals Biosimilar Insulin Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Paras Biopharmaceuticals Biosimilar Insulin Main Business and Markets Served

      • 11.3.4 Paras Biopharmaceuticals Biosimilar Insulin Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Biogenomics

      • 11.4.1 Biogenomics Company Details

      • 11.4.2 Biogenomics Biosimilar Insulin Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Biogenomics Biosimilar Insulin Main Business and Markets Served

      • 11.4.4 Biogenomics Biosimilar Insulin Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Teva Pharmaceuticals

      • 11.5.1 Teva Pharmaceuticals Company Details

      • 11.5.2 Teva Pharmaceuticals Biosimilar Insulin Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Teva Pharmaceuticals Biosimilar Insulin Main Business and Markets Served

      • 11.5.4 Teva Pharmaceuticals Biosimilar Insulin Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Wockhardt

      • 11.6.1 Wockhardt Company Details

      • 11.6.2 Wockhardt Biosimilar Insulin Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Wockhardt Biosimilar Insulin Main Business and Markets Served

      • 11.6.4 Wockhardt Biosimilar Insulin Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Samsung Bioepis

      • 11.7.1 Samsung Bioepis Company Details

      • 11.7.2 Samsung Bioepis Biosimilar Insulin Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Samsung Bioepis Biosimilar Insulin Main Business and Markets Served

      • 11.7.4 Samsung Bioepis Biosimilar Insulin Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Gan&Lee Pharmaceuticals

      • 11.8.1 Gan&Lee Pharmaceuticals Company Details

      • 11.8.2 Gan&Lee Pharmaceuticals Biosimilar Insulin Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Gan&Lee Pharmaceuticals Biosimilar Insulin Main Business and Markets Served

      • 11.8.4 Gan&Lee Pharmaceuticals Biosimilar Insulin Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    • 11.9 Pfizer

      • 11.9.1 Pfizer Company Details

      • 11.9.2 Pfizer Biosimilar Insulin Sales, Price, Value and Gross Profit (2017-2022)

      • 11.9.3 Pfizer Biosimilar Insulin Main Business and Markets Served

      • 11.9.4 Pfizer Biosimilar Insulin Product Portfolio

      • 11.9.5 Recent Research and Development Strategies

    • 11.10 Sedico

      • 11.10.1 Sedico Company Details

      • 11.10.2 Sedico Biosimilar Insulin Sales, Price, Value and Gross Profit (2017-2022)

      • 11.10.3 Sedico Biosimilar Insulin Main Business and Markets Served

      • 11.10.4 Sedico Biosimilar Insulin Product Portfolio

      • 11.10.5 Recent Research and Development Strategies

    • 11.11 Eli Lilly

      • 11.11.1 Eli Lilly Company Details

      • 11.11.2 Eli Lilly Biosimilar Insulin Sales, Price, Value and Gross Profit (2017-2022)

      • 11.11.3 Eli Lilly Biosimilar Insulin Main Business and Markets Served

      • 11.11.4 Eli Lilly Biosimilar Insulin Product Portfolio

      • 11.11.5 Recent Research and Development Strategies

    12 Global Biosimilar Insulin Market Outlook by Types and Applications to 2028

    • 12.1 Global Biosimilar Insulin Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Rapid Acting Insulins Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Short Acting Insulins Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Intermediate Insulins Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.4 Global Long Lasting Insulins Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Biosimilar Insulin Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Clinic Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Medical Center Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Biosimilar Insulin Market Analysis and Outlook to 2028

    • 13.1 Global Biosimilar Insulin Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.2.2 Canada Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Biosimilar Insulin Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.3.2 UK Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.3.3 Spain Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.3.5 France Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.3.6 Italy Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.3.8 Finland Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.3.9 Norway Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.3.11 Poland Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.3.12 Russia Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Biosimilar Insulin Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.4.2 Japan Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.4.3 India Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Biosimilar Insulin Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.5.3 Chile Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.5.6 Peru Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Biosimilar Insulin Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.6.3 Oman Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Biosimilar Insulin Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Biosimilar Insulin Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Biosimilar Insulin Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Biosimilar Insulin Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Biosimilar Insulin

    • Figure of Biosimilar Insulin Picture

    • Table Global Biosimilar Insulin Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Biosimilar Insulin Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Rapid Acting Insulins Consumption and Growth Rate (2017-2022)

    • Figure Global Short Acting Insulins Consumption and Growth Rate (2017-2022)

    • Figure Global Intermediate Insulins Consumption and Growth Rate (2017-2022)

    • Figure Global Long Lasting Insulins Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Clinic Consumption and Growth Rate (2017-2022)

    • Figure Global Medical Center Consumption and Growth Rate (2017-2022)

    • Figure Global Biosimilar Insulin Consumption by Country (2017-2022)

    • Table North America Biosimilar Insulin Consumption by Country (2017-2022)

    • Figure United States Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Canada Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Mexico Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Table Europe Biosimilar Insulin Consumption by Country (2017-2022)

    • Figure Germany Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure UK Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Spain Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Belgium Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure France Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Italy Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Denmark Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Finland Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Norway Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Sweden Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Poland Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Russia Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Turkey Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Table APAC Biosimilar Insulin Consumption by Country (2017-2022)

    • Figure China Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Japan Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure India Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure South Korea Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Thailand Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Singapore Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Philippines Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Table South America Biosimilar Insulin Consumption by Country (2017-2022)

    • Figure Brazil Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Colombia Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Chile Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Argentina Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Peru Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Table GCC Biosimilar Insulin Consumption by Country (2017-2022)

    • Figure Bahrain Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Oman Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Qatar Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Table Africa Biosimilar Insulin Consumption by Country (2017-2022)

    • Figure Nigeria Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure South Africa Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Egypt Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure Algeria Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Table Oceania Biosimilar Insulin Consumption by Country (2017-2022)

    • Figure Australia Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Biosimilar Insulin Consumption and Growth Rate (2017-2022)

    • Table Geropharm Company Details

    • Table Geropharm Biosimilar Insulin Sales, Price, Value and Gross Profit (2017-2022)

    • Table Geropharm Biosimilar Insulin Main Business and Markets Served

    • Table Geropharm Biosimilar Insulin Product Portfolio

    • Table Julphar Gulf Pharmaceutical Industries Company Details

    • Table Julphar Gulf Pharmaceutical Industries Biosimilar Insulin Sales, Price, Value and Gross Profit (2017-2022)

    • Table Julphar Gulf Pharmaceutical Industries Biosimilar Insulin Main Business and Markets Served

    • Table Julphar Gulf Pharmaceutical Industries Biosimilar Insulin Product Portfolio

    • Table Paras Biopharmaceuticals Company Details

    • Table Paras Biopharmaceuticals Biosimilar Insulin Sales, Price, Value and Gross Profit (2017-2022)

    • Table Paras Biopharmaceuticals Biosimilar Insulin Main Business and Markets Served

    • Table Paras Biopharmaceuticals Biosimilar Insulin Product Portfolio

    • Table Biogenomics Company Details

    • Table Biogenomics Biosimilar Insulin Sales, Price, Value and Gross Profit (2017-2022)

    • Table Biogenomics Biosimilar Insulin Main Business and Markets Served

    • Table Biogenomics Biosimilar Insulin Product Portfolio

    • Table Teva Pharmaceuticals Company Details

    • Table Teva Pharmaceuticals Biosimilar Insulin Sales, Price, Value and Gross Profit (2017-2022)

    • Table Teva Pharmaceuticals Biosimilar Insulin Main Business and Markets Served

    • Table Teva Pharmaceuticals Biosimilar Insulin Product Portfolio

    • Table Wockhardt Company Details

    • Table Wockhardt Biosimilar Insulin Sales, Price, Value and Gross Profit (2017-2022)

    • Table Wockhardt Biosimilar Insulin Main Business and Markets Served

    • Table Wockhardt Biosimilar Insulin Product Portfolio

    • Table Samsung Bioepis Company Details

    • Table Samsung Bioepis Biosimilar Insulin Sales, Price, Value and Gross Profit (2017-2022)

    • Table Samsung Bioepis Biosimilar Insulin Main Business and Markets Served

    • Table Samsung Bioepis Biosimilar Insulin Product Portfolio

    • Table Gan&Lee Pharmaceuticals Company Details

    • Table Gan&Lee Pharmaceuticals Biosimilar Insulin Sales, Price, Value and Gross Profit (2017-2022)

    • Table Gan&Lee Pharmaceuticals Biosimilar Insulin Main Business and Markets Served

    • Table Gan&Lee Pharmaceuticals Biosimilar Insulin Product Portfolio

    • Table Pfizer Company Details

    • Table Pfizer Biosimilar Insulin Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Biosimilar Insulin Main Business and Markets Served

    • Table Pfizer Biosimilar Insulin Product Portfolio

    • Table Sedico Company Details

    • Table Sedico Biosimilar Insulin Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sedico Biosimilar Insulin Main Business and Markets Served

    • Table Sedico Biosimilar Insulin Product Portfolio

    • Table Eli Lilly Company Details

    • Table Eli Lilly Biosimilar Insulin Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eli Lilly Biosimilar Insulin Main Business and Markets Served

    • Table Eli Lilly Biosimilar Insulin Product Portfolio

    • Figure Global Rapid Acting Insulins Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Short Acting Insulins Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Intermediate Insulins Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Long Lasting Insulins Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Medical Center Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Biosimilar Insulin Consumption Forecast by Country (2022-2028)

    • Table North America Biosimilar Insulin Consumption Forecast by Country (2022-2028)

    • Figure United States Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Biosimilar Insulin Consumption Forecast by Country (2022-2028)

    • Figure Germany Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Biosimilar Insulin Consumption Forecast by Country (2022-2028)

    • Figure China Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Biosimilar Insulin Consumption Forecast by Country (2022-2028)

    • Figure Brazil Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Biosimilar Insulin Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Biosimilar Insulin Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Biosimilar Insulin Consumption Forecast by Country (2022-2028)

    • Figure Australia Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Biosimilar Insulin Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US